Subjective well being of patients receiving atypical antipsychotics as monotherapy or cotherapy with mood stabilizers - DIDAXI

Cross - Sectional study requiring one visit at the investigators office for the data collection. - Target Group: Patients that suffer from Bipolar Disorder Type 1. - YMRS - HAMILTON and GAF scales are going to be used to assess the clinical outcome. The findings are going to be based on the different scores reported by Specialists (before the patients started to use as a therapy atypical antipsychotics / at the time that the visit actually takes place for the cause of the study.) We predefine the time period that the patient should be using atypical antipsychotics at minimum (2 months). - The first 9 consecutive patients that visit the Specialist and meet the entry criteria and signs the ICF will be recruited in the study.